868565-58-6

Basic information

• Product Name: D-glycero-Pentonic acid, 2,3-dideoxy-3-[[(2S)-1-oxo-2-[[(phenylMethoxy)carbonyl]aMino]propyl]aMino]-5-O-(2,3,5,6-tetrafluorophenyl)-, 1,1-diMethylethyl ester, (4ξ)- (9CI)
• Synonyms: D-glycero-Pentonic acid, 2,3-dideoxy-3-[[(2S)-1-oxo-2-[[(phenylMethoxy)carbonyl]aMino]propyl]aMino]-5-O-(2,3,5,6-tetrafluorophenyl)-, 1,1-diMethylethyl ester, (4ξ)- (9CI);(3S)-tert-butyl 3-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate
• CAS NO: 868565-58-6
• Molecular Formula: C₂₆H₃₀F₄N₂O₇
• Molecular Weight: 558.5192128
• Mol File: 868565-58-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: D-glycero-Pentonic acid, 2,3-dideoxy-3-[[(2S)-1-oxo-2-[[(phenylMethoxy)carbonyl]aMino]propyl]aMino]-5-O-(2,3,5,6-tetrafluorophenyl)-, 1,1-diMethylethyl ester, (4ξ)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: D-glycero-Pentonic acid, 2,3-dideoxy-3-[[(2S)-1-oxo-2-[[(phenylMethoxy)carbonyl]aMino]propyl]aMino]-5-O-(2,3,5,6-tetrafluorophenyl)-, 1,1-diMethylethyl ester, (4ξ)- (9CI)(868565-58-6)
• EPA Substance Registry System: D-glycero-Pentonic acid, 2,3-dideoxy-3-[[(2S)-1-oxo-2-[[(phenylMethoxy)carbonyl]aMino]propyl]aMino]-5-O-(2,3,5,6-tetrafluorophenyl)-, 1,1-diMethylethyl ester, (4ξ)- (9CI)(868565-58-6)

Safety Data

• Hazardous Substances Data: 868565-58-6(Hazardous Substances Data)

Upstream product

• 868565-57-5 (3S)-3-[(N-benzyloxycarbonyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 254751-09-2 (S)-tert-butyl 3-(((benzyloxy)carbonyl)amino)-4-oxo-5-(2,3,5,6-tetrafluoro phenoxy)pentanoate 
• 1142-20-7 N-Cbz-Ala 
• 254751-10-5 (3S,4RS)-3-amino-5-(2',3',5',6'-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 254750-84-0 tert-butyl (3S)-3-(benzyloxycarbonylamino)-4-hydroxy-5-(2,3,5,6-tetrafluorophenoxy)pentanoate 
• 769-39-1 2,3,5,6-tetraflourophenol 
• 153088-76-7 (S)-3-benzyloxycarbonylamino-5-bromo-4-oxo-pentanoic acid tert-butyl ester 
• 5545-52-8 Z-D(tBu)-OH 
• 3401-36-3 (N-benzyloxycarbonyl)-L-alanine N-hydroxysuccinimide ester 
• 3408-50-2 [(N-benzyloxycarbonyl)-L-alaninyl]-L-aspartic acid [beta]-tert-butyl ester 
• 3057-74-7 L-Asp(t-Bu) 
• 868565-55-3 (3S)-3-[(N-benzyloxycarbonyl)-L-alaninyl]amino-5-bromo-4-oxopentanoic acid tert-butyl ester 

Downstream Products

• 254750-81-7 (3S)-3-(alaninyl)amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 
• 254750-83-9 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-oxopentanoic acid tert-butyl ester 
• 254750-82-8 (3S)-3-[N-(N′-(2-tert-butylphenyl)oxamyl)alaninyl]amino-5-(2′,3′,5′,6′-tetrafluorophenoxy)-4-hydroxypentanoic acid tert-butyl ester 

Relevant articles and documents

LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR

A compound represented by formula (I), a pharmaceutically acceptable salt or tautomer thereof, and an application of the compound as a caspase inhibitor.

TREATMENT OF THE COMPLICATIONS OF CHRONIC LIVER DISEASE

Provided herein are methods and compositions for treatment of a portal hypertension and cirrhosis by administering a of a caspase inhibitor alone or in combination with current treatments for portal hypertension. Also provided are methods and compositions